Please select the option that best describes you:
How long would you continue atezolizumab/bevacizumab in a patient with HCC who is having a prolonged response with stable disease?
Answer from: Medical Oncologist at Academic Institution
Similar to how this was done in the phase 3 trial of atezolizumab/bevacizumab (vs sorafenib), I continue until progression or intolerance. Finn et al., PMID 32402160
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
This is a perfectly reasonable approach that @Noelle K. LoConte outlined. However, I'm not sure that there is any specific reason to privilege the approach from this study above any other approach (such as discontinuation of immunotherapy after two years of therapy, as is commonly done in other dise...
Answer from: Medical Oncologist at Academic Institution
I agree with @Noelle K. LoConte. With stable disease, treatment should continue until progression or intolerance. For those patients with a complete response (5-10%), there has been some data to suggest that stopping therapy is possible; however, recurrence can range from 14-40% (Lim et al., PMID 39...